| Literature DB >> 28025511 |
Beata Shiratori1, Jingge Zhao2, Masao Okumura3, Haorile Chagan-Yasutan4, Hideki Yanai5, Kazue Mizuno6, Takashi Yoshiyama7, Tadashi Idei8, Yugo Ashino9, Chie Nakajima10, Yasuhiko Suzuki11, Toshio Hattori12.
Abstract
Elevated matricellular proteins (MCPs), including osteopontin (OPN) and galectin-9 (Gal-9), were observed in the plasma of patients with Manila-type tuberculosis (TB) previously. Here, we quantified plasma OPN, Gal-9, and soluble CD44 (sCD44) by enzyme-linked immunosorbent assay (ELISA), and another 29 cytokines by Luminex assay in 36 patients with pulmonary TB, six subjects with latent tuberculosis (LTBI), and 19 healthy controls (HCs) from Japan for a better understanding of the roles of MCPs in TB. All TB subjects showed positive results of enzyme-linked immunospot assays (ELISPOTs). Spoligotyping showed that 20 out of 36 Mycobacterium tuberculosis (MTB) strains belong to the Beijing type. The levels of OPN, Gal-9, and sCD44 were higher in TB (positivity of 61.1%, 66.7%, and 63.9%, respectively) than in the HCs. Positive correlations between OPN and Gal-9, between OPN and sCD44, and negative correlation between OPN and ESAT-6-ELISPOT response, between chest X-ray severity score of cavitary TB and ESAT-6-ELISPOT response were observed. Instead of OPN, Gal-9, and sCD44, cytokines G-CSF, GM-CSF, IFN-α, IFN-γ, IL-12p70, and IL-1RA levels were higher in Beijing MTB-infected patients. These findings suggest immunoregulatory, rather than inflammatory, effect of MCPs and can advance the understanding of the roles of MCPs in the context of TB pathology.Entities:
Keywords: Beijing genotype MTB; CD44; galectin-9; osteopontin; tuberculosis
Mesh:
Substances:
Year: 2016 PMID: 28025511 PMCID: PMC5297654 DOI: 10.3390/ijms18010019
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Characteristics of HC, LTBI, and TB individuals.
| Parameter | Ref. | HC ( | LTBI ( | TB ( | |
|---|---|---|---|---|---|
| Antropometric data | |||||
| Age: year; median (range) | 34 (19–67) | 63 (36–71) | 59.5 (19–86) | 0.007 | |
| Gender: male; | 12 (63) | 5 (83) | 28 (78) | 0.43 | |
| Laboratory findings: median (range) | |||||
| RBC (106/μL) | Male 4.5–5.5; | na | 4.65 (4.35–5.12) | 4.44 (2.72–5.57) | 0.443 |
| Hemoglobin (g/dL) | 14–18 | na | 14.6 (14.2–15.3) | 13.1 (8.9–17.5) | 0.064 |
| Hematocrit (%) | 40–48 | na | 43.6 (40.9–46.0) | 39.65 (25.5–51.9) | 0.059 |
| WBC (103/μL) | 4.5–11 | na | 7.64 (5.34–9.96) | 7.33 (3.84–16.22) | 0.945 |
| Neutrophil (%) | 38–80 | na | 57.35(51.9–75.7) | 75.2 (57.0–89.6) | 0.014 |
| Lymphocyte (%) | 15–40 | na | 33.1 (18.2–39.6) | 14.1 (2.8–34.8) | 0.007 |
| Monocyte (%) | 4–7 | na | 6 (4.9–7.7) | 6.9 (3.4–11.2) | 0.035 |
| Eosinophil (%) | 0–8 | na | 1.1 (0.4–4.1) | 1.4 (0–11.4) | 0.902 |
| Platelet (103/μL) | 140–390 | na | 267 (203–280) | 305 (125–564) | 0.228 |
| CRP (mg/dL) | 0–0.3 | na | 0.055 (0.04–0.07) | 6 (0.04–21.5) | 0.002 |
| Genotype (Beijing strain MTB %) | 73.0, year 2010, Japan | na | na | 55.6 | na |
| ALT (Units) | 4–37 | na | 20.5 (11–29) | 15 (8–103) | na |
| Creatinine (mg/dL) | 0.5–1.5 | na | 0.74 (0.42–11) | 0.71 (0.57–0.86) | na |
Age differences among the groups were analyzed by the Kruskal-Wallis test, gender differences by the Chi-square test, and laboratory findings by the Mann-Whitney test; p < 0.05 means a significant difference; na: not applicable.
Biomarker levels measured by Luminex assay and ELISA in HCs and TB patients.
| Biomarker | HC | TB | |
|---|---|---|---|
| IFNγ (pg/mL) | 4.46 (0.42–19.38) | 8.13 (2.12–41) | 0.0065 |
| IL-8 (pg/mL) | 1.585 (0.38–7.52) | 7.26 (0.6–31.07) | <0.0001 |
| IP-10 (pg/mL) | 235.8 (132.2–472.8) | 864.6 (219.3–3051) | <0.0001 |
| TNFα (pg/mL) | 3.88 (2.83–8.34) | 10.11 (2.19–24.83) | <0.0001 |
| OPN (ng/mL) | 19.63 (9.31–111.64) | 28.62 (10.59–170) | 0.012 |
| Gal-9 (ng/mL) | 14.0 (0–120) | 171.5 (0–470) | 0.0002 |
| sCD44 (ng/mL) | 118.57 (91.02–141.41) | 159.66 (98.89–346.2) | <0.0001 |
| FL-OPN (nmol/mL) | 5.20 (2.83–14.45) | 1.75 (0.52–43.91) | >0.05 |
| rtOPN (pmol/mL) | 0 (0–26.73) | 0.87 (0–347.95) | >0.05 |
Figure 1OPN, Gal-9 and sCD44 in groups under study. Comparison of plasma levels of OPN (A); Gal-9 (B); and sCD44 (C) among HC, LTBI, and TB patients. Correlations among OPN, Gal-9, and sCD44 in TB patients (D–F); comparison of OPN (G); Gal-9 (H); and sCD44 (I) between Beijing and non-Beijing genotype.
Figure 2ELISPOTs reaction and OPN levels. ELISPOT assays are plotted as the number of specific PBMCs against the indicated stimulus (A); a negative correlation was observed between the ELISPOT for ESAT-6 and OPN in TB (B); and this correlation was not seen in the LTBI group (C).
Figure 3OPN, full-length OPN, n-half OPN, and ESAT-6 SFC count in TB patients. A comparison of plasma levels of OPN with full-length OPN (A) and with n-half OPN (B); and a comparison of ESAT-6 ELISPOT SFC counts with full-length OPN (C) and with n-half OPN (D).
Correlations of OPN, Gal-9, and sCD44 with other laboratory parameters and biomarkers in TB patients.
| Measurements | OPN | sCD44 | Gal-9 |
|---|---|---|---|
| r ( | r ( | r ( | |
| WBC (103/μL) | Ns | 0.388 (0.019) | Ns |
| Neutrophil (%) | 0.517 (<0.0001) | Ns | Ns |
| Lymphocyte (%) | −0.569 (<0.0001) | −0.558 (<0.0001) | Ns |
| CRP (mg/dL) | 0.757 (<0.0001) | 0.534 (0.001) | Ns |
| IL-8 (pg/mL) | 0.474 (0.013) | 0.524 (0.005) | Ns |
| IP-10 (pg/mL) | 0.420 (0.029) | 0.542 (0.003) | Ns |
| TNFα | Ns | 0.446 (0.020) | Ns |
| ALT | Ns | Ns | 0.375 (0.024) |
| Cre | Ns | Ns | 0.377 (0.023) |
Ns: not significant.
Sensitivity and specificity.
| Analytes | Youden Index | Cutoff | Sensitivity (%) | Specificity (%) | AUC | Comparison | ||
|---|---|---|---|---|---|---|---|---|
| OPN | 0.4006 | 25.1 | 61.1 | 79 | 0.706 | |||
| Gal-9 | 0.6667 | 120 | 66.7 | 100 | 0.798 | |||
| sCD44 | 0.6389 | 141.4 | 63.9 | 100 | 0.846 | |||
| IP-10 | 0.8593 | 400.3 | 92.6 | 93.3 | 0.965 | |||
| Anti-TBGL IgG | 0.5058 | 1.6 | 61.1 | 89.4 | 0.762 | |||
A cutoff was calculated based on TB and HC data from the Youden index. The discriminatory power of each test was evaluated by the area under curve (AUC) comparison. , , a significant difference between the AUCs of the indicated tests; , p < 0.05, , p < 0.001.
Figure 4Sensitivity and specificity analysis for OPN, anti-TBGL IgG, IP-10, and sCD44. Comparison between ATB and HCs (A,B), no significant difference between the areas under curve (AUC) of OPN and anti-TBGL IgG, IP-10, or sCD44, p > 0.05. Strong discriminatory power of IP-10 and sCD44; p < 0.0001 for both (A). Comparison between ATB and LTBI, no significant discriminatory power of OPN, Gal-9, and sCD44 in LTBI and ATB (p > 0.05) due to the inadequacy of LTBI subjects (C). No significant difference between the AUC of OPN and Gal-9, between Gal-9 and sCD44, but difference between OPN and sCD44 (p = 0.014) (C).
Comparison of laboratory findings between TB patients with and without cavity lung formation.
| Parameter | Normal Value (Range) | Cavity (−) ( | Cavity (+) ( | |
|---|---|---|---|---|
| Hemoglobin (g/dL) | 14–18 | 13.8 (8.9–17.5) | 12.4 (9.9–14.7) | 0.0454 |
| Hematocrit (%) | 40–48 | 42 (25.5–51.9) | 37.5 (28.4–41.4) | 0.0208 |
| Monocyte (%) | 4–7 | 6.2 (3.4–10) | 8.3 (4.9–10.2) | 0.0054 |
| CRP (mg/dL) | 0–0.3 | 3.27 (0.04–21.5) | 8.67 (0.08–17.97) | 0.0478 |
| IP-10 (pg/mL) | 132.2–472.8 | 751.5 (219.3–2735) | 1570 (369.7–3051) | 0.0408 |
| Anti-TBGL IgG (U/mL) | <2 | 13.3 (0.1–62.6) | 1.11 (0–72.6) | 0.0123 |
| CXR Score | 0 | 92.46 (82.4–100) | 131.84 (104.34–140) | 0.0001 |
CXR score and biomarkers in TB patients.
| Parameter | CXR Scorer ( | CXR Scorer ( | |
|---|---|---|---|
| Cavity (+) | Cavity (−) | ||
| Monocytes (%) | 0.502 (0.003) | Ns | Ns |
| OPN | Ns | Ns | Ns |
| sCD44 | Ns | Ns | Ns |
| IP-10 | 0.452 (0.027) | Ns | Ns |
| Gal-9 | Ns | Ns | Ns |
| IL-12p70 | 0.517 (0.01) | Ns | 0.574 (0.032) |
| ESAT-6 SFC | Ns | −0.6185 (0.0425) | Ns |
Ns: no significant.
Laboratory and biomarker values in patients infected by Beijing or non-Beijing strains of Mycobacterium tuberculosis (MTB).
| Parameter | HC | Beijing Type ( | Non-Beijing Type ( | |
|---|---|---|---|---|
| Laboratory findings | ||||
| RBC (106/μL) | na. | 4.28 (2.72–5.16) | 4.64 (3.86–5.57) | 0.0465 |
| Total protein (g/dL) | na. | 7.05 (5.41–8.03) | 7.69 (6.54–8.14) | 0.0323 |
| Biomarker (pg/mL) | ||||
| G-CSF | 48.48 (12.19–90.49) | 56.94 (21.69–106.36) | 38.12 (14.06–73.07) | 0.0388 |
| GM-CSF | 4.24 (0.44–18.98) | 12.29 (0.83–48.8) | 5.84 (0.44–14.6) | 0.0300 |
| IFNα | 11.07 (0–56.49) | 32.87 (1.67–60.81) a | 7.53 (0–40.97) | 0.0034 |
| IFNγ | 4.46 (0.42–19.38) | 16.02 (3.09–41) a | 4.71 (2.12–17.84) | 0.0141 |
| IL-12p70 | 2.74 (1.35–15.06) | 8.22 (1.85–29.77) | 2.62 (0.03–7.13) | 0.0007 |
| IL-1RA | 17.79 (0–81.26) | 51.96 (8.56–217.37) a | 14.02 (0–78.44) | 0.0095 |
| IP-10 | 235.78 (132.2–472.75) | 877.12 (219.29–2814.69) a | 864.57 (369.67–3051.48) b | >0.05 |
| Cavity | 0 | 8 (40) | 4 (25) | >0.05 |
| CXR score | 0 | 102.23 (82.4–140) | 109.74 (82.77–140) | >0.05 |
Differences among the groups in terms of laboratory biomarkers were analyzed by the Kruskal-Wallis test; p < 0.05 indicates a significant difference between Beijing and non-Beijing MTB groups; a indicates a significant difference between groups Beijing MTB and HC, p < 0.05; b indicates a significant difference between groups non-Beijing MTB and HC; p < 0.05. na., no applicable.